SciBX: Science-Business eXchange Contents: January 19 2012, Volume 5/ Issue 3

< TABLE OF CONTENTS January 19 2012, Volume 5 / Issue 3 Analysis Cover Story Translational Notes Targets and Mechanisms The Distillery: Therapeutics Autoimmune disease Cancer Endocrine/metabolic disease Hematology Infectious disease Inflammation Neurology Other Transplantation Various The Distillery: Techniques Disease models Drug platforms Advertisement SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Spreadin' the news Kai-Jye Lou doi:10.1038/scibx.2012.59 SciBX's roundup of 2011 public-private partnership data shows the emergence of New York as a translational hub, the impact of nongovernmental funding on infectious disease research compared with the more muted VC support of this area, and the high interest of foreign companies in funding research in China. Full Text | PDF Translational Notes Top Seeing the (En)light Chris Cain doi:10.1038/scibx.2012.60 AstraZeneca and Novo Nordisk have come off the sidelines to partner with Enlight Biosciences, making them the sixth and seventh pharmas currently working with Enlight to form platform companies. Full Text | PDF Scripps' partnering rethink Lev Osherovich doi:10.1038/scibx.2012.61 The Scripps Research Institute has decided that the kind of broad deals it used to do with industry do not work anymore. Instead, the institute now hopes to forge a series of smaller, more focused collaborations with midsize biotechs. Full Text | PDF Targets and Mechanisms Top Heat shock and awe Tim Fulmer doi:10.1038/scibx.2012.62 U.S. researchers have identified several small molecules that decrease toxic protein aggregation in vitro. The first-generation compounds have been licensed by Proteostasis and are proof of concept for the biotech's approach to treating protein misfolding diseases like Huntington's and cystic fibrosis. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Transglutaminase 2 (TGM2; TG2) doi:10.1038/scibx.2012.63 In vitro studies identified autoantibody binding sites of TG2 that could be blocked to help treat celiac disease. Full Text | PDF Cancer Top ADP-ribosylation factor 1 (ARF1) doi:10.1038/scibx.2012.64 Mouse studies identified an ARF1 inhibitor that could help treat breast cancer. Full Text | PDF Mucin 1 (MUC1; CD227) doi:10.1038/scibx.2012.65 Mouse studies suggest an immunotherapy based on a MUC1 glycopeptide could help treat breast cancer. Full Text | PDF Nerve growth factor (NGF) doi:10.1038/scibx.2012.66 Cell culture and patient tissue studies suggest pro-NGF could be antagonized to treat breast cancer. Full Text | PDF Taspase threonine aspartase 1 (TASP1) doi:10.1038/scibx.2012.67 Cell culture and mouse studies identified a TASP1 inhibitor that could help treat breast cancer and gliomas. Full Text | PDF Checkpoint kinase 1-short (Chk1-S) doi:10.1038/scibx.2012.68 In vitro and mouse studies suggest increasing levels of Chk1-S may help treat cancer. Full Text | PDF Fibronectin 1 (FN1; FN) doi:10.1038/scibx.2012.69 Mouse studies identified an FN1-targeting antibody-drug conjugate that could help treat cancer. Full Text | PDF Not applicable doi:10.1038/scibx.2012.70 Mouse studies suggest activating autophagy or increasing ATP release from tumor cells could help treat cancer. Full Text | PDF Sirtuin 1 (SIRT1) doi:10.1038/scibx.2012.71 In vitro and mouse studies suggest inhibiting SIRT1 could increase the efficacy of Gleevec imatinib in CML. Full Text | PDF Endocrine/metabolic disease Top Fibroblast growth factor receptor 1 (FGFR1; CD331); fibroblast growth factor 21 (FGF21) doi:10.1038/scibx.2012.72 A study in mice suggests an agonist mAb of FGFR1 could help treat type 2 diabetes. Full Text | PDF Sphingosine 1-phosphate receptor doi:10.1038/scibx.2012.73 Studies in mice suggest that agonizing sphingosine 1-phosphate receptors could help treat diabetes. Full Text | PDF Hematology Top CXC chemokine receptor 4 (CXCR4; NPY3R); chemokine CXC motif ligand 12 (CXCL12; SDF-1); CXCR7 doi:10.1038/scibx.2012.74 In vitro and mouse studies suggest inhibiting the CXCR4/CXCR7/SDF-1 signaling pathway could help treat or prevent hemolytic uremic syndrome following Escherichia coli infection. Full Text | PDF Infectious disease Top UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC) doi:10.1038/scibx.2012.75 In vitro and mouse studies identified hydroxamic acid–based LpxC inhibitors that could help treat Gram-negative bacterial infections. Full Text | PDF Niemann-Pick C1-like protein (NPC1L1) doi:10.1038/scibx.2012.76 In vitro and mouse studies suggest NPC1L1 inhibitors could help prevent HCV infection. Full Text | PDF Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); RIPK3 (RIP3) doi:10.1038/scibx.2012.77 Mouse studies suggest that inhibition of RIPK1 and/or RIPK3 could help prevent systemic inflammatory response syndrome (SIRS). Full Text | PDF Inflammation Top Matrix metalloproteinase 9 (MMP9) doi:10.1038/scibx.2012.78 Mouse studies identified antibodies that inhibit MMP9 to help treat inflammatory diseases. Full Text | PDF Neurology Top Nicotinic acetylcholine receptor α4β2 doi:10.1038/scibx.2012.79 In vitro and mouse studies suggest two new classes of nicotinic acetylcholine receptor α4β2 partial agonists could help treat depression. Full Text | PDF Heat shock transcription factor 1 (HSF1) doi:10.1038/scibx.2012.80 An in vitro screen identified small molecule compounds that activated the heat shock response and could help treat HD and other protein misfolding diseases. Full Text | PDF Mitochondrial complex 1 (MC-1) doi:10.1038/scibx.2012.81 Rat studies suggest a fusion protein consisting of the rabies virus glycoprotein (RVG) linked to a cytomegalovirus (CMV)-derived RNA sequence could help treat PD. Full Text | PDF Other Top Ryanodine receptor 1 (RyR1) doi:10.1038/scibx.2012.82 Mouse studies suggest 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) could help prevent heat-induced sudden death caused by RyR1 mutations. Full Text | PDF Transplantation Top Haptoglobin (HP) doi:10.1038/scibx.2012.83 Mouse studies suggest that antagonizing HP could help prevent graft rejection. Full Text | PDF Various Top p38 Mitogen-activated protein kinase (p38 MAPK; MAPK14) doi:10.1038/scibx.2012.84 In vitro and mouse studies identified a compound that could help guide the development of selective p38 MAPK–targeted therapeutics for cancer and inflammatory diseases. Full Text | PDF Distillery: Techniques Disease models Top Induced pluripotent stem (iPS) cell model for Timothy syndrome doi:10.1038/scibx.2012.85 A study in cell culture suggests patient-derived iPS cells could help identify therapies for Timothy syndrome, a form of autism spectrum disorder. Full Text | PDF Drug platforms Top Isoxazole compounds for pancreatic islet b cell regeneration doi:10.1038/scibx.2012.86 A study in cell culture suggests 3,5-disubstitute isoxazoles could be useful for regenerating islet b cells in type 1 diabetes. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.